Improving models of chronic lymphocytic leukemia

April 7, 2016, Journal of Clinical Investigation

Chronic lymphocytic leukemia (CLL) is a common form of adult leukemia that results in the progressive expansion of abnormal lymphocytes. The cell type that gives rise to CLL is still unclear, though evidence suggests that a subset of immature B cell lymphocytes is transformed during development. Because of the heterogeneity of this cancer, it has not been possible to create a mouse model that faithfully recapitulates all aspects of this disease.

In this issue of JCI Insight, Nicholas Chiorazzi and colleagues at the Feinstein Institute for Medical Research sought to understand a model of CLL in which patient cancer cells are transplanted into immunocompromised mice. They previously showed that patient cells initially engrafted into mice and mimicked the disease, but the engraftment did not persist long term. In this study, they show that human malignant B cells from CLL patients differentiate into antibody secreting plasma cells in their murine model in the presence of patient-derived T cells.

Their findings reveal why are not maintained in their and suggest the possibility that therapies promoting differentiation could merit further exploration for CLL.

Explore further: Stem cells central to pathogenesis of mature lymphoid tumors

More information: Piers E.M. Patten et al. Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6–deficient process, JCI Insight (2016). DOI: 10.1172/jci.insight.86288

Related Stories

Stem cells central to pathogenesis of mature lymphoid tumors

August 15, 2011
New research suggests that blood stem cells can be involved in the generation of leukemia, even when the leukemia is caused by the abnormal proliferation of mature cells. The study, published by Cell Press in the August 16th ...

Agent selectively targets malignant B cells in chronic leukemia, study shows

May 3, 2011
A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James ...

The mouse that ROR'ed: ROR1 oncogene combines with another to accelerate, worsen blood cancer

January 2, 2014
Researchers at the University of California, San Diego School of Medicine report that an oncogene dubbed ROR1, found on chronic lymphocytic leukemia (CLL) B cells but not normal adult tissues, acts as an accelerant when combined ...

Study confirms target of potent chronic leukemia drug

December 19, 2013
A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) helps confirm that a molecule targeted ...

Protein-protein interaction activates and fuels leukemia cell growth

December 21, 2015
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 ...

Monoclonal antibody targets, kills leukemia cells

March 25, 2013
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.

Recommended for you

New therapeutic gel shows promise against cancerous tumors

February 21, 2018
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results ...

Kinase inhibitor larotrectinib shows durable anti-tumor abilities

February 21, 2018
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors ...

Five novel genetic changes linked to pancreatic cancer risk

February 21, 2018
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and collaborators from over 80 other ...

Similarities found in cancer initiation in kidney, liver, stomach, pancreas

February 21, 2018
Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that ...

Research could change how doctors treat leukemia and other cancers fed by fat

February 21, 2018
Obesity and cancer risk have a mysterious relationship, with obesity increasing the risk for 13 types of cancer. For some cancers—including pediatric cancers—obesity affects survival rates, which are lower for people ...

New technique predicts gene resistance to cancer treatments

February 21, 2018
Yale School of Public Health researchers have developed a new method to predict likely resistance paths to cancer therapeutics, and a methodology to apply it to one of the most frequent cancer-causing genes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.